Zacks Research Issues Negative Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Zacks Research cut their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a note issued to investors on Monday, December 9th. Zacks Research analyst R. Department now anticipates that the company will earn ($1.48) per share for the quarter, down from their prior estimate of ($1.47). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.17) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the firm earned ($1.41) EPS.

Several other analysts have also commented on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Barclays reduced their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Wednesday. Finally, Chardan Capital restated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $77.93.

CRISPR Therapeutics Trading Down 5.0 %

Shares of NASDAQ CRSP opened at $45.40 on Thursday. CRISPR Therapeutics has a twelve month low of $43.42 and a twelve month high of $91.10. The firm has a 50-day moving average of $48.83 and a two-hundred day moving average of $51.29. The company has a market capitalization of $3.88 billion, a price-to-earnings ratio of -16.04 and a beta of 1.62.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Advisors Inc. OK raised its stake in shares of CRISPR Therapeutics by 8.1% during the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after buying an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $2,375,000. International Assets Investment Management LLC bought a new position in shares of CRISPR Therapeutics in the 3rd quarter worth $1,825,000. Krilogy Financial LLC boosted its position in shares of CRISPR Therapeutics by 92.9% in the 2nd quarter. Krilogy Financial LLC now owns 20,872 shares of the company’s stock worth $1,127,000 after purchasing an additional 10,050 shares during the last quarter. Finally, FMR LLC grew its stake in shares of CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after purchasing an additional 23,075 shares during the period. 69.20% of the stock is owned by institutional investors.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,382 shares of company stock valued at $2,744,179 over the last ninety days. 4.10% of the stock is owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.